HONZ PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.68 CNY | +1.08% |
|
+6.36% | -20.27% |
| Sales 2021 | 837M 115M 9.25B | Sales 2022 | 536M 73.94M 5.92B | Capitalization | 2.8B 386M 30.93B |
|---|---|---|---|---|---|
| Net income 2021 | 11M 1.52M 122M | Net income 2022 | -188M -25.95M -2.08B | EV / Sales 2021 | 5.07 x |
| Net Debt 2021 | 334M 46.07M 3.69B | Net Debt 2022 | 313M 43.2M 3.46B | EV / Sales 2022 | 5.81 x |
| P/E ratio 2021 |
356
x | P/E ratio 2022 |
-14.9
x | Employees | 843 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 34.57% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.08% | ||
| 1 week | +6.36% | ||
| Current month | -7.87% | ||
| 1 month | -6.59% | ||
| 3 months | -18.32% | ||
| 6 months | -22.77% | ||
| Current year | -20.27% |
1 week
4.28
4.71
1 month
4.165.27
Current year
3.756.34
1 year
3.757.20
3 years
3.7512.46
5 years
3.7512.46
10 years
3.7535.73
| Managers | Title | Age | Since |
|---|---|---|---|
Jiang Tao Hong
CEO | Chief Executive Officer | 54 | 18/12/19 |
Peng Fei Cheng
DFI | Director of Finance/CFO | 47 | 29/09/21 |
Jiang You Hong
CHM | Chairman | 60 | 27/12/07 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Li Ping Hong
BRD | Director/Board Member | 56 | 19/12/07 |
Jiang You Hong
CHM | Chairman | 60 | 27/12/07 |
Youquan Li
BRD | Director/Board Member | 55 | 18/12/19 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 4.68 | +1.08% | 5,861,100 |
| 25/04/24 | 4.63 | +1.31% | 5,922,500 |
| 24/04/24 | 4.57 | +2.47% | 5,457,900 |
| 23/04/24 | 4.46 | +1.59% | 5,182,544 |
| 22/04/24 | 4.39 | -0.23% | 4,323,300 |
End-of-day quote Shenzhen S.E., April 25, 2024
More quotes
HONZ PHARMACEUTICAL CO., LTD., formerly HAINAN HONZ PHARMACEUTICAL CO., LTD., is principally engaged in the research, development, production and distribution of drugs for children. The Company provides western medicines and Chinese patent drugs, including antipyretic and analgesic drugs, cold drugs, antibiotics drugs, respiratory system drugs, digestant and arresting convulsion drugs, as well as nutrition drugs, among others. The Company's products include nimesulide granules, cefminox sodium for injection, Zhike Juhong granules, Ganmao Qingre granules, artificial cow-bezoar and chlorphenamine maleate granules, cefaclor granules, carbocisteine granules, Jianerle granules, pediatric four vitaminsand calcium gluconate granules, as well as ribavirin pellets and Norfloxacin capsules for adults.
Sector
Pharmaceuticals
Calendar
28/04/2024
- Q1 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -20.27% | 291M | |
| +19.62% | 43.34B | |
| +20.44% | 21.96B | |
| +10.86% | 14.09B | |
| +13.07% | 13.64B | |
| +37.46% | 11.43B | |
| -8.59% | 6.86B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +8.46% | 5.22B |
- Stock Market
- Equities
- 300086 Stock
